H-2Db HPV16 E7 Tetramer-RAHYNIVTF-PE

MBL Life Sciences

Catalog No.: MBL-TS-5008-1C

Product Description

Anti-mouse CD8 clone choice is critical when mouse MHC I tetramers, as some clones, including 53-6.7, lead to high background staining of all CD8+ T cells, rather than the antigen-specific ones. For best results, clone KT15 in FITC (MBL-K0227-4) is recommended. Additional information can be found in the datasheet that accompanies mouse class I tetramers, as well as the following reference containing a protocol for performing a cross titration series for optimization: Current Protocols in Immunology, MHC-Peptide tetramers to Visualize Antigen-Specific T Cells, Section 17.3.23-24, Supplement 65

T lymphocytes play a central role in immune system. Total T cell and T cell subset counts are measured by detection of various cell surface molecules. Enumeration of CD8+ antigen-specific T cells requires cognate recognition of the T cell receptor (TCR) by a class I MHC/peptide complex. This can be done using class I MHC Tetramers which are composed of a complex of four H-2 MHC class I molecules each bound to the specific peptide1), 2) and conjugated with a fluorescent protein. Thus, T-Select MHC Tetramer assays allow quantitation of the total T cell population specific for a given peptide complexed in a particular MHC molecule. Furthermore, since binding does not depend on functional pathways, this population includes all specific CD8+ T cells regardless of functional status. Measurements may be performed in whole blood or isolated lymphocyte/splenocyte or thymocyte cell preparations3). Specific cell staining is accomplished by incubating the sample with the T-Select MHC Tetramer reagent, then washing away excess Tetramer. The number of Tetramer positive lymphocytes is then determined by flow cytometry.

Product Specifications

• Application: FC
• Reactivity: Mouse
• Conjugation: PE
• Immunogen: HPV16 E7
• Peptide Sequence: RAHYNIVTF
• Class: Class I
• Sequence Location: 49-57
• MHC Allele: H-2D^b

Citations for H-2Db HPV16 E7 Tetramer-RAHYNIVTF-PE – 2 Found

Sato-Kaneko, Fumi; Yao, Shiyin; Ahmadi, Alast; Zhang, Shannon S; Hosoya, Tadashi; Kaneda, Megan M; Varner, Judith A; Pu, Minya; Messer, Karen S; Guiducci, Cristiana; Coffman, Robert L; Kitaura, Kazutaka; Matsutani, Takaji; Suzuki, Ryuji; Carson, Dennis A; Hayashi, Tomoko; Cohen, Ezra Ew. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. Jci Insight. 2017;2(18) 

Quayle, Steven N; Girgis, Natasha; Thapa, Dharma R; Merazga, Zohra; Kemp, Melissa M; Histed, Alex; Zhao, Fan; Moreta, Miguel; Ruthardt, Paige; Hulot, Sandrine; Nelson, Alyssa; Kraemer, Lauren D; Beal, Dominic R; Witt, Luke; Ryabin, Jessica; Soriano, Jonathan; Haydock, Mark; Spaulding, Emily; Ross, John F; Kiener, Peter A; Almo, Steven; Chaparro, Rodolfo; Seidel, Ronald; Suri, Anish; Cemerski, Saso; Pienta, Kenneth J; Simcox, Mary Ellen. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research. 2020;26(8):1953-1964.